Cell-specific sequencing of translating mRNAs elucidates signaling pathology that can be targeted to reverse neuropathic pain
Main text
Neuropathic pain is a devastating disease with extraordinarily poor treatment outcomes. Existing first-line treatments produce only 30% pain relief in the majority of patients (1). Chemotherapy-induced peripheral neuropathy (CIPN) is the primary doselimiting side effect of cancer treatment and no drugs are approved to treat this form of neuropathic pain (2) . Peripheral pain sensing neurons, called nociceptors, are the cellular origin of pain caused by neuropathies (3) . The dynamics of nociceptors gene expression throughout the development of painful neuropathy at the genome scale is opaque. We employed the translating ribosome affinity purification (TRAP) technology (4), using the Nav1.8 Cre mouse to achieve sensory neuron-specific ribosome tagging with enrichment in the nociceptor population. We used these Nav1.8-TRAP mice to identify transcripts associated with ribosomes specifically expressed in nociceptors isolated from animals with or without CIPN. This tool elucidates pathology in a broad signaling network that centers around RagA and mechanistic target of rapamycin complex 1 (mTORC1) signaling that plays a central role in development of neuropathic pain. Our work provides new insights into the complex interplay of lysosomal mTORC1 signaling as a disease-causing factor in peripheral neuropathy. We demonstrate how this information provides new strategies for development of the first disease-modifying agents for neuropathic pain treatment, a debilitating and pervasive clinical problem.
To generate nociceptor-enriched ribosome-tagged mice, Nav1.8 cre mice were crossed with Rosa26 fs-TRAP (5) , to express eGFP fused to the ribosomal L10a protein in Nav1.8-positive neurons. To ensure the specificity of our approach, we characterized expression of the transgene in the DRG (Fig. 1A) . We found that eGFP-L10a-positive neurons primarily co-localized with small diameter peripherin-positive neurons (81% ± 3.1) while a smaller proportion of eGFP-labelled neurons co-expressed NF200, a marker of large diameter neurons (40.1% ± 2.8) (Fig. 1B,C) . The percentage of eGFP-L10apositive neurons was equally distributed between non-peptidergic (86.7% ± 2.3) and peptidergic neurons (78.7%± 2.7) (Fig.1C) . We did not observe eGFP-L10a expression in non-neuronal cells in the DRG. Thus, this approach specifically labels sensory neurons including a substantial subset of neurons that are involved in nociception.
The Nav1.8-TRAP was used to characterize the translatome of DRG neurons that express Nav1.8 using mRNAs isolated with immunoprecipitation (IP) of translating ribosomes (TRAP-seq) (6) . First, we determined that IP of the eGFP-L10a from DRGs of control and Nav1.8-TRAP mouse strains yielded a specific IP of eGFP-L10a using eGFP antibodies (Fig. S1A) . We also used IP combined with RT-qPCR for several mRNAs that are known to be enriched in nociceptors (7) to demonstrate integrity of the IP-mRNA complex ( Fig. S1B-C-D) . These experiments demonstrate that the Nav1.8-TRAP approach can be used to tag ribosomes and capture mRNAs from nociceptive DRG
neurons.
A large amount of starting material is required to successfully isolate ribosomeassociated mRNAs from Nav1.8-TRAP cells. We determined that DRGs from cervical, thoracic and lumbar levels from 4 animals were minimally required for a single biological replicate of accurate TRAP-seq in this tissue. Since a goal of our experiments was to assess the nociceptor translatome in neuropathic pain, this prompted us to utilize a neuropathy model where all DRGs are affected such as CIPN. Almost 70% of cancer patients report symptoms of peripheral neuropathy during chemotherapeutic treatment and this is the primary dose-limiting side effect of chemotherapy treatment (8) . Notably, the pathophysiology of CIPN, which is the most common cause of termination of chemotherapy (2) remains unknown.
We treated Nav1.8-TRAP mice with the commonly used chemotherapeutic agent, paclitaxel (4 mg/kg every other day, intraperitoneally, for a total of 8 days), which causes a robust small and large-fiber neuropathy in rodents and humans. To first determine whether paclitaxel increases the excitability of nociceptors at all vertebral levels we isolated cervical, thoracic and lumbar DRGs from mice treated with vehicle or paclitaxel and performed patch clamp electrophysiology. Paclitaxel treatment caused spontaneous activity and increased nociceptor excitability Subsequent experiments were also carried out in males and females (Supplemental Table 2 ) and no differences were observed between sexes. On day 10 after the start of paclitaxel or vehicle treatment, we collected eGFP-L10a IPs from Nav1.8-TRAP mice for RNA sequencing. To gain insight into the specificity of the Nav1.8-TRAP approach, we analyzed a subset of genes that are known to be enriched in different cell populations in the DRG. This analysis demonstrated that TRAP-seq allowed the isolation of translating mRNAs in a cell-type specific manner. Indeed, neuronal mRNAs such as Calca (CGRPα), Calcb (CGRPβ) or Scn10a (Nav1.8) were enriched in TRAP fractions whereas glial markers (Aldh1l1, Gfap) and endothelial specific genes (Cldn5, Esam) were depleted. (Fig. 1D ).
From all biological replicates we sequenced input mRNA, equivalent to the DRG transcriptome, and TRAP mRNAs associated with translating ribosomes in the Nav1.8 subset of DRG neurons. This approach allowed us to make comparisons of transcriptional and translational changes in response to neuropathic pain. Gene expression values (TPM) were normalized to the 90 th percentile for each biological replicate and the empirical probability density function (PDF) of the normalized expression level (upper decile (ud)TPM) was plotted for the input and TRAP fractions ( Fig. S3A,B) . The PDF function displayed 2 peaks (Fig. S3A,B ) and the inflexion point was used to set the threshold expression values according to the sequencing depth. After further filtering, based on consistent expression among biological replicates, we included a total of 8270 genes in the final analysis.
We then plotted the cumulative frequency distribution as a function of the log 2fold change for each of these genes in vehicle-versus paclitaxel-treated biological replicates and the 95 th percentile was used to set the threshold fold change values for the input and TRAP fractions ( Combining this dataset with single cell RNA sequencing from existing data sources (10, 11) allowed us to infer translation efficiencies (TEs) for all mRNAs translated in Nav1.8 neurons creating a rich resource for understanding steady state translation of mRNAs expressed in nociceptors (https://www.utdallas.edu/bbs/painneurosciencelab/sensoryomics/cipntrap/browse.ht ml). We examined families of genes for any systematic differences in TEs for mRNAs expressed in Nav1.8-positive nociceptors (e.g. ion channels, G-protein coupled receptors and kinases). Interestingly, we observed that ion channels and GPCR tend to show higher TEs compared to other gene families such as kinases, RNA-binding proteins or transcription factors (Fig. S5A) . With paclitaxel treatment we found a clear increase in TE for Trpv1, which has been shown to be up-regulated after paclitaxel (12) , and P2rx2, and a decrease in TE for Chrna6. These latter two genes interact such that Chrna6 inhibits the pronociceptive activity of P2rx2 (13) suggesting a reciprocal translational regulation event that would be expect to enhance pain sensitivity ( Fig. S5B ).
Having established alterations in the nociceptor translatome with paclitaxel treatment, we then sought to examine whether there were motifs in the 5' untranslated regions (UTRs) of mRNAs up-regulated after CIPN. We found an enrichment for 3 motifs, among them a terminal oligopyrimidine tract (TOP)-like element which is associated with mTORC1-mediated translation control (14) (Fig. S6 ). Another enriched motif was a G-quartet-like sequence suggesting translation control by the RNA helicase eIF4A (15) ( Fig. S6) . Interestingly, eIF4a3 was highly translated after CIPN (Supplemental Table 4 ).
The final motif was an A/G rich sequence with no known function.
We then investigated what classes of genes were significantly enriched in the up and down regulated mRNA TRAP-seq dataset using the EnrichR tool (16) . First, validating that this approach can identify pathological changes in nociceptors that have already been linked to CIPN (17), reactive oxygen species and mitochondrial dysregulation signatures were significantly enriched in the paclitaxel-treated TRAP-seq dataset.
Likewise, several translationally up-regulated mRNAs have already been identified in the CIPN literature using independent methods, such as caspase 6 (18) . We also found a significant enrichment of genes involved in the regulation of cap-dependent translation, the lysosomal complex and mTORC1 signaling (Fig. 1G ). Closer examination of the up-regulated and down-regulated mRNA lists for TRAP-seq with EnrichR analysis led us to further investigate a network of mTORC1 signaling-associated proteins that we hypothesized are critical for pathology causing CIPN.
We confirmed changes in steady state protein levels for a panel of targets identified in the TRAP-seq dataset with increased translation efficiency with paclitaxel treatment ( Fig. 2A-B) including mTOR (Fig. 2B) , and Esyt1 ( Fig. S7A-C) . The concordance between measurement indicates that TRAP-seq can reliably predict increases in protein expression in DRG after CIPN. Based on increased mTOR protein levels we also examined downstream and associated targets of mTOR where we noted increases in p-4EBP1 expression ( Fig. 2B ) but no differences in phosphorylation or total protein levels for ERK, AKT or, surprisingly, ribosomal protein S6 (Fig. S8A-B) . We also found that eIF4E phosphorylation was increased with paclitaxel treatment (Fig. 2B) . These findings suggest a selective increase in signaling via a subset of proteins that control translation of genes involved in neuronal plasticity (19, 20) . To test this hypothesis, we asked if mTOR inhibition or genetic loss of the phosphorylation site for mitogen activated protein kinase interacting kinase (MNK) on the cap-binding protein eIF4E (eIF4E S209A ) would impair CIPN.
We used the ATP competitive mTORC1/2 inhibitor AZD8055 to examine the influence of mTOR inhibition on paclitaxel-induced pain. While a robust reduction in mechanical hypersensitivity occurred with the first intrathecal injection of AZD8055, the magnitude of this effect was decreased upon subsequent treatments (Fig. 2C) . We attribute this rapid onset, tolerance-like effect to the known phenomena of feedback signaling in the mTOR pathway (21, 22) . We then turned to a genetic approach to examine disrupted MNK-eIF4E signaling. eIF4E S209A mice treated with paclitaxel showed decreased mechanical and thermal hypersensitivity compared to their WT littermates ( Fig. 2D-E) . While this suggests decreased CIPN pain in the absence of eIF4E phosphorylation, we determined this empirically using the conditioned place preference (CPP) paradigm (23) with retigabine as the conditioning agent, as has been described previously (24) . Importantly, WT mice had a clear preference for the retigabine-paired chamber demonstrating relief of spontaneous pain. On the other hand, eIF4E S209A mice showed no preference for the retigabine-paired chamber. This indicates an absence of spontaneous pain in these mice (Fig. 2F) .
Given the strong behavioral phenotype of eIF4E S209A mice in CIPN, we turned to a clinical candidate drug, eFT508 (25) . eFT508 is a potent MNK1/2 inhibitor and blocks eIF4E phosphorylation in vitro and in vivo. We used this compound to examine whether targeted blockade of the MNK-eIF4E signalling axis inhibits and/or reverses paclitaxelinduced pain. We first tested the potency of eFT508 in cultured DRGs neurons.
Treatment with eFT508 reduced eIF4E phosphorylation by 90% without affecting ERK, 4EBP or AKT phosphorylation or expression ( Fig. 2G and Fig. S9 ). eFT508 did not reduce bulk translation (Fig. S10A-B) . This parallels previous findings that Mnk1/2 controls the translation of a specific subset of mRNAs (19, 26) . Paclitaxel-treated mice given eFT508 after full development of CIPN showed a dose-related reversal of mechanical and thermal hypersensitivity (Fig. 2H-I) . Also, the animals did not show sign of tolerance with multiple treatments and the effect of eFT508 was completely absent in eIF4E S209A mice demonstrating the specificity of te drug (Fig. S11) . Consistent with an action on nociceptors, 80% of eGFP-L10a+ neurons exhibited strong p-eIF4E signal (Fig. 2J-K) . No signal for the p-eIF4E antibody was observed in the eIF4E S209A mice, indicative of the specificity of the antibody (Fig. S12) .
Our findings suggest a link between increased translation of mTOR complex proteins and MNK-mediated eIF4E phosphorylation as a causative factor in paclitaxel- phosphorylation. The RagA-Ragulator complex controls mTORC1 activity in response to amino acid flux across the lysosomal membrane (28, 29) and requires activity of the RagA, but not the RagB, GTPase (30, 31) . RagA exists in a complex with RagC while RagB forms a complex with RagD (30, 31) . Our TRAP-seq comparison demonstrates that genes corresponding to the components of the RagA-Ragulator-mTORC1 complex are preferentially translated after paclitaxel treatment (Fig. 3A) . In particular, there was a 3.5 fold increase in the number of normalized reads mapping to the Rraga mRNA, encoding the RagA GTPase amino acid sensor for mTORC1 ( Fig. 3B-C) .
Other components of the RagA-Ragulator-mTORC1 complex including Lamtor5, Lamp2, Atp6v1a, Fkbp1a, Fkbp1b, Ywhaq and Mtor also showed a consistent increase in translation with paclitaxel treatment (Fig. 3B-C) . Interestingly, known negative regulators of mTORC1 including Akt1s1, encoding PRAS40, and the γ 2 subunit of AMPK (Prkag2) showed decrease translation efficiency (Fig. 3A and D) . These findings indicate a fundamental change in the mTORC1 signaling network in Nav1.8 expressing neurons in CIPN that could be indicative of altered protein biosynthesis or related to other functions of mTORC1, such as lipid homeostasis (32). A component of this latter pathway, Soat2, was also selectively translated with paclitaxel and can be inhibited by avasimibe (33). Repeated treatment with this drug had no effect on paclitaxel-induced pain (Fig. S13) . Given the behavioral observations with eIF4E S209A mice, the effect of eFT508 in CIPN and negative findings with avasimibe, we further focused on translation regulation mechanisms as the key causative factor in paclitaxel-induced neuropathic pain.
We validated that RagA protein levels were increased in DRG by paclitaxel treatment (Fig. 3E) . We also found that RagA protein expression was significantly lower in eIF4E S209A mice compared to WT mice, although mRNA levels were equal in the two strains of mice (Fig. 3F) . These findings suggested that eIF4E phosphorylation controls
RagA translation in CIPN. To test this, we treated eIF4E S209A mice with paclitaxel and failed to observe an effect from paclitaxel on RagA protein in DRGs from these mice (Fig. 3G) . Moreover, the MNK1/2 inhibitor eFT508 decreased RagA protein levels both in cultured DRG neurons (Fig. 3H) and in vivo (Fig. 3I) . 4EBP1 phosphorylation was also decreased in the DRG of eFT508-treated mice linking altered RagA translation to downstream mTORC1 activity (Fig. 3I) . Interestingly, MNK1/2 inhibition also decreased the protein expression level of Lamtor5 in DRG neurons (Fig. S14) .
Two MNK isoforms are known to phosphorylate eIF4E, however, MNK2 shows constitutive kinase activity while MNK1 is induced by cellular stimuli (34). We reasoned that MNK1-mediated phosphorylation of eIF4E might control RagA protein expression and regulate paclitaxel-induced CIPN. MNK1 -/mice showed a 40% reduction in RagA protein levels in DRG compared to WT and a significant reduction in eIF4E phosphorylation while upstream signaling pathways were unchanged (Fig. 3J, Fig.   S15A ). When we co-examined eIF4E phosphorylation with RagA expression in mouse DRG we observed correlated expression for RagA and p-eIF4E. This was increased by paclitaxel treatment and strongly suppressed by eFT508 with an 80% correlation coefficient indicating that increases or decreases in eiF4E phosphorylation can reliably influence the level of RagA translation (Fig. 3K) . We then assessed paclitaxel-induced CIPN in MNK1 -/mice and observed a profound deficit in the development of neuropathic pain (Fig. 3L ) consistent with observations in eIF4E S209A mice. Finally, we examined whether transient MNK1/2 inhibition could decrease spontaneous activity in DRG neurons taken from paclitaxel treated mice. These neurons showed robust spontaneous activity that was almost completely suppressed by eFT508 treatment within 20 min (Fig 3M and Supplemental Table 1-B) . This effect was reversible indicating that eFT508 is not toxic to DRG neurons in vitro.
We used nociceptor translational profiling in a mouse model of neuropathic pain to provide a rich resource for probing translational control in pain plasticity and reveal high quality targets for the potential generation of disease modifying therapies for a currently intractable disease. Our work demonstrates dysregulation of the mTORC1 signaling network in CIPN that reveals a complex interplay between eIF4E-mediated translation control of RagA and mTORC1 function (Fig. S15B) . Our experiments support a model wherein MNK1-mediated phosphorylation of eIF4E controls the translation of RagA mRNA creating a link between these distinct signaling pathways. In the context of CIPN, increased eIF4E phosphorylation leads to enhanced RagA protein levels driving mTORC1 activation and neuropathic pain. Our findings demonstrate that MNK and eIF4E phosphorylation can be targeted genetically or with eFT508, a drug in late phase clinical trials, to prevent or reverse CIPN pain. These discoveries can be used to enhance the efficacy of cancer chemotherapy treatment by reducing the primary 
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